Literature DB >> 18804360

Impact of pulmonary hypertension on gas exchange and exercise capacity in patients with pulmonary fibrosis.

Sven Gläser1, Oliver Noga, Beate Koch, Christian F Opitz, Bernd Schmidt, Bettina Temmesfeld, Marcus Dörr, Ralf Ewert, Christoph Schäper.   

Abstract

Pulmonary hypertension is a relevant interceding morbidity in patients with pulmonary fibrosis that has significant impact on exercise tolerance and outcome. The aim of this study was to further characterize the exercise intolerance, dyspnoea and ventilatory inefficiency of patients with pulmonary fibrosis in the presence or absence of pulmonary hypertension via cardiopulmonary exercise testing. Thirty-four patients underwent pulmonary function testing, symptom-limited exercise testing on a bicycle and dyspnoea evaluation according to the BORG scale. Pulmonary hypertension was assessed by echocardiography and in a subset of patient's right heart catheterization. Sixteen of 34 patients with pulmonary fibrosis revealed pulmonary hypertension. While all study patients did not differ in lung functions and demographic characteristics, patients suffering from pulmonary hypertension showed a significantly impaired exercise tolerance and worsened ventilatory inefficiency. The extent of pulmonary artery pressure elevation impacted significantly on ventilatory inefficiency. In addition, the increased ventilatory requirements significantly influenced the extent of dyspnoea in patients with pulmonary hypertension. We conclude that pulmonary hypertension has a significant impact on exercise capacity and dyspnoea in patients with interstitial lung disease (ILD). The further impairment of exercise capacity as well as the extent of dyspnoea in patients with interceding PHT is attributable to a significantly impaired ventilatory inefficiency.

Entities:  

Mesh:

Year:  2008        PMID: 18804360     DOI: 10.1016/j.rmed.2008.08.005

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  24 in total

Review 1.  Cardiopulmonary exercise testing in the assessment of pulmonary hypertension.

Authors:  Ross Arena; Marco Guazzi; Jonathan Myers; Daniel Grinnen; Daniel E Forman; Carl J Lavie
Journal:  Expert Rev Respir Med       Date:  2011-04       Impact factor: 3.772

2.  Prevalence of pulmonary hypertension in patients with idiopathic pulmonary fibrosis: correlation with physiological parameters.

Authors:  D Papakosta; G Pitsiou; Z Daniil; M Dimadi; E Stagaki; A Rapti; K Antoniou; A Tzouvelekis; T Kontakiotis; S Tryfon; V Polychronopoulos; D Bouros
Journal:  Lung       Date:  2011-06-11       Impact factor: 2.584

3.  Impact of pulmonary hypertension on exercise performance in patients with interstitial lung disease undergoing evaluation for lung transplantation.

Authors:  Hilary F Armstrong; P Christian Schulze; Matthew Bacchetta; Wilawan Thirapatarapong; Matthew N Bartels
Journal:  Respirology       Date:  2014-05-06       Impact factor: 6.424

Review 4.  Right ventricular dysfunction in chronic lung disease.

Authors:  Todd M Kolb; Paul M Hassoun
Journal:  Cardiol Clin       Date:  2012-05       Impact factor: 2.213

Review 5.  Pharmacologic therapies for idiopathic pulmonary fibrosis, past and future.

Authors:  Bashar S Staitieh; Elisabetta A Renzoni; Srihari Veeraraghavan
Journal:  Ann Med       Date:  2015-01-22       Impact factor: 4.709

6.  MRC chronic Dyspnea Scale: Relationships with cardiopulmonary exercise testing and 6-minute walk test in idiopathic pulmonary fibrosis patients: a prospective study.

Authors:  Effrosyni D Manali; Panagiotis Lyberopoulos; Christina Triantafillidou; Likourgos F Kolilekas; Christina Sotiropoulou; Joseph Milic-Emili; Charis Roussos; Spyros A Papiris
Journal:  BMC Pulm Med       Date:  2010-05-28       Impact factor: 3.317

7.  EACPR/AHA Scientific Statement. Clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations.

Authors:  Marco Guazzi; Volker Adams; Viviane Conraads; Martin Halle; Alessandro Mezzani; Luc Vanhees; Ross Arena; Gerald F Fletcher; Daniel E Forman; Dalane W Kitzman; Carl J Lavie; Jonathan Myers
Journal:  Circulation       Date:  2012-09-05       Impact factor: 29.690

8.  Determinants of 6-minute walk distance in patients with idiopathic pulmonary fibrosis undergoing lung transplant evaluation.

Authors:  Mary K Porteous; Belinda N Rivera-Lebron; Maryl Kreider; James Lee; Steven M Kawut
Journal:  Pulm Circ       Date:  2016-03       Impact factor: 3.017

9.  The benefits of exercise training in interstitial lung disease: protocol for a multicentre randomised controlled trial.

Authors:  Leona Dowman; Christine F McDonald; Catherine Hill; Annemarie Lee; Kathryn Barker; Claire Boote; Ian Glaspole; Nicole Goh; Annemarie Southcott; Angela Burge; Rebecca Ndongo; Alicia Martin; Anne E Holland
Journal:  BMC Pulm Med       Date:  2013-02-01       Impact factor: 3.317

10.  Pulmonary hypertension in patients with idiopathic pulmonary fibrosis - the predictive value of exercise capacity and gas exchange efficiency.

Authors:  Sven Gläser; Anne Obst; Beate Koch; Beate Henkel; Anita Grieger; Stephan B Felix; Michael Halank; Leonhard Bruch; Tom Bollmann; Christian Warnke; Christoph Schäper; Ralf Ewert
Journal:  PLoS One       Date:  2013-06-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.